PointState Capital’s Puma Biotechnology PBYI Stock Holding History

PointState Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-315,183	Closed	-$21.4M	–	194
2018 Q1	$21.4M	Buy	315,183 +89,951	+40%	+$6.74M	0.23%	72
2017 Q4	$22.3M	Sell	225,232 -188,778	-46%	-$21.1M	0.22%	76
2017 Q3	$49.6M	Sell	414,010 -191,350	-32%	-$17.8M	0.42%	54
2017 Q2	$52.9M	Sell	605,360 -165,640	-21%	-$9.27M	0.57%	44
2017 Q1	$28.7M	Buy	+771,000	New	+$28.1M	0.3%	63
2015 Q3	–	Sell	-40,000	Closed	-$4.67M	–	130
2015 Q2	$4.67M	Buy	+40,000	New	+$7.24M	0.05%	109
2014 Q3	–	Sell	-20,000	Closed	-$1.32M	–	132
2014 Q2	$1.32M	Buy	20,000 +5,000	+33%	+$356K	0.02%	119
2014 Q1	$1.56M	Sell	15,000 -30,000	-67%	-$3.53M	0.02%	108
2013 Q4	$4.66M	Buy	+45,000	New	+$2.64M	0.06%	116
2013 Q3	–	Sell	-100,000	Closed	-$4.44M	–	155
2013 Q2	$4.44M	Buy	+100,000	New	+$3.53M	0.08%	109

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PointState Capital's PBYI Position: Q2 2018 in Review

PointState Capital sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 315,183 shares — an estimated $21.4M sold.

PointState Capital first reported a position in PBYI in Q2 2013 and held it in 10 quarters. The position peaked at $52.9M in Q2 2017. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

PointState Capital reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
PointState Capital sold 315,183 Puma Biotechnology shares in Q2 2018, an estimated $21.4M.
PointState Capital first reported a position in Puma Biotechnology in Q2 2013 and held it in 10 quarters.
PointState Capital's Puma Biotechnology position peaked at $52.9M in Q2 2017.
174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.